The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Pandemic Antiviral Discovery (PAD) -- Henipavirus – Request for proposals 2022
The Novo Nordisk Foundation, Open Philanthropy, and the Bill & Melinda Gates Foundation have launched the Pandemic Antiviral Discovery (PAD) initiative to catalyze discovery and early development of antiviral medicines for future pandemics. This initiative's first request for proposals (RFP) will focus on henipavirus, a subfamily of paramyxovirus that includes Nipah virus - a pathogen with an estimated fatality rate of 40% to 75%. Researchers from around the world are encouraged to submit proposals; the application deadline is May 5, 2022.
The focus of this PAD Request for Proposals (RfP) is henipavirus, a subfamily of paramyxovirus that includes Nipah virus—a pathogen with an estimated fatality rate of 40% to 75%. Researchers from around the world are encouraged to submit proposals.
This RfP will support projects that seek to elucidate the molecular determinants of henipavirus replication, pathogenesis and transmission for the purpose of developing therapeutic discovery programs targeting virus and/or host-specific targets important for virus replication. Projects can be of both novel and exploratory nature and of later-stage validation/developmental nature.
Areas of Interest
Specific areas of interest include:
- Biomarkers of henipavirus pathogenesis in humans to facilitate drug discovery programs and clinical evaluation of antiviral therapies.
- Identification and validation of virus and/or host targets necessary for henipavirus replication that could serve as starting points for therapeutic discovery.
- Inhibitors of virus and/or host targets that are broadly active across paramyxoviruses with a preference for henipaviruses.
- Novel tools and assays for studying henipavirus replication and pathogenesis that do not require BSL-4 containment.
- Target based approaches for henipavirus antiviral discovery and development.
Projects on vaccines, antibody therapy, and epidemiology will not be considered for funding.
If the eligibility criteria listed below are not adhered to in the submitted proposal, it will receive an administrative rejection • PAD seeks to actively engage researchers from all over the world as part of the drug discovery process, but applicants must be established investigators with their own line of research and must be employed for the duration of the project at the administrating institution registered in the proposal. • The administrating institution/organization must be able to accept and manage the potential grant. Projects can be anchored at any type of research organization, including academia, not-for profit and commercial organizations. • The scope of the project must be within the scientific scope of this RfP and support the PAD aspirations. • An applicant (i.e., the principal investigator (PI) responsible for the project and submitting the proposal) may submit only one proposal to this specific RfP. Different PI’s can be anchored at the same institution/organization. The proposal must contain all information requested in these guidelines and be submitted via NORMA. Applications submitted by post or e-mail will not be considered.
A total of up to USD 10 million is expected to be allocated to proposals submitted to this RfP, but this amount is not fixed and may be updated depending on the quantity and quality of the proposals. The number of proposals supported will depend on the quality and expected budget, e.g., PAD may support 5 exploratory projects of approximately USD 2 million or one later-stage validation project of approximately USD 10 million.